Zynex (NASDAQ:ZYXI) Releases Q4 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of at least $0.09 for the period, compared to the consensus estimate of $0.10. The company issued revenue guidance of at least $53.6 million, compared to the consensus revenue estimate of $53.30 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Analyst Ratings Changes

A number of research firms recently weighed in on ZYXI. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Zynex in a report on Wednesday, September 4th.

Zynex Price Performance

NASDAQ:ZYXI traded up $0.23 during trading hours on Thursday, reaching $8.59. 148,955 shares of the company traded hands, compared to its average volume of 173,434. The firm’s 50-day moving average is $7.96 and its 200-day moving average is $9.23. The stock has a market cap of $272.65 million, a P/E ratio of 47.78 and a beta of 0.54. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22. Zynex has a 1-year low of $7.04 and a 1-year high of $13.77.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, July 25th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The company had revenue of $49.88 million for the quarter, compared to analyst estimates of $51.99 million. Zynex had a net margin of 3.12% and a return on equity of 14.15%. Zynex’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.09 EPS. Equities research analysts expect that Zynex will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Zynex

In related news, Director Joshua R. Disbrow bought 7,000 shares of the stock in a transaction on Monday, July 29th. The shares were purchased at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the acquisition, the director now owns 72,000 shares in the company, valued at $599,040. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Zynex news, Director Joshua R. Disbrow purchased 7,000 shares of Zynex stock in a transaction on Monday, July 29th. The shares were bought at an average price of $8.32 per share, with a total value of $58,240.00. Following the purchase, the director now directly owns 72,000 shares in the company, valued at $599,040. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Anna Lucsok sold 8,083 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the transaction, the chief operating officer now directly owns 16,980 shares in the company, valued at approximately $136,349.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 52.13% of the stock is owned by insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.